Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14356/2745
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdhikari, Prabhat-
dc.date.accessioned2025-10-09T08:36:17Z-
dc.date.available2025-10-09T08:36:17Z-
dc.date.issued2025-04-11-
dc.identifier.urihttps://hdl.handle.net/20.500.14356/2745-
dc.language.isoen_USen_US
dc.publisherCenter for American Medical Specialists (CAMS) Kathmandu, Nepalen_US
dc.titleAvoid fluoroquinolones as empiric therapy, reserve for tuberculosisen_US
dc.typePresentationen_US
Appears in Collections:Day II, 11 April 2025; Parallel session IV, Hall A; Infectious Disease and Epidemic Preparedness (Chairs: prof. Dr. Jeevan B Sherchand and Dr. Ranjan Bhatt)

Files in This Item:
File Description SizeFormat 
AVOID FLUOROQUINOLONES AS EMPIRIC THERAPY, RESERVE FOR.pdfpresentation.1.07 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.